Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Adding nebivolol to ongoing antihypertensive therapy improves blood pressure and response rates in patients with uncontrolled stage I–II hypertension

Journal of Human Hypertension volume 24, pages 64–73 (2010)Cite this article

An Erratum to this article was published on 13 May 2010

Abstract

This study assessed blood pressure (BP) reductions and response rates following addition of nebivolol to ongoing antihypertensive therapy in patients with uncontrolled stage I–II hypertension despite antihypertensive treatment. Patients with an average sitting diastolic BP (SiDBP) ⩾90 and ⩽109 mm Hg while taking an antihypertensive regimen were included in this double-blind, placebo-controlled, parallel-group study. The primary efficacy end point was reduction from baseline to week 12 in mean trough SiDBP. In total, 669 patients were randomized to once-daily nebivolol 5, 10 or 20 mg or placebo. Addition of nebivolol 5, 10 and 20 mg significantly reduced BP; placebo-subtracted least squares mean reductions in trough SiDBP were −3.3, −3.5 and −4.6 mm Hg, respectively (P<0.001) and −5.7, −3.7 and −6.2 mm Hg in trough sitting systolic BP (SiSBP), respectively (P⩽0.015). Adding nebivolol 5–20 mg resulted in significantly more responders (SiDBP <90 or ⩾10 mm Hg reduction; range: 53.0–65.1 vs 41.3% with placebo; P⩽0.028) and significantly better control rates (SiSBP/SiDBP <140/90 mm Hg; range: 41.3–52.7 vs 29.3% with placebo; P⩽0.029). Nebivolol was well tolerated; the incidence of adverse events with nebivolol was similar to that with placebo (40.2 vs 38.9%, respectively; P=0.763). Addition of once-daily nebivolol to ongoing antihypertensive therapy provided significant additional BP reductions and better response rates in patients with uncontrolled hypertension and was well tolerated.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J . Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365: 217–223.

    Article  Google Scholar 

  2. Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens 2002; 4: 393–404.

    Article  Google Scholar 

  3. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206–1252.

    Article  CAS  Google Scholar 

  4. Pierdomenico SD, Lapenna D, Bucci A, Di Tommaso R, Di Mascio R, Manente BM et al. Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. Am J Hypertens 2005; 18: 1422–1428.

    Article  Google Scholar 

  5. Sica DA . Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs 2002; 62: 443–462.

    Article  CAS  Google Scholar 

  6. Weber MA . The role of the new beta-blockers in treating cardiovascular disease. Am J Hypertens 2005; 18: 169S–176S.

    Article  CAS  Google Scholar 

  7. Jacob S, Rett K, Henriksen EJ . Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of beta-blocking agents? Am J Hypertens 1998; 11: 1258–1265.

    Article  CAS  Google Scholar 

  8. Kamp O, Sieswerda GT, Visser CA . Comparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertension. Am J Cardiol 2003; 92: 344–348.

    Article  CAS  Google Scholar 

  9. Van de Water A, Janssens W, Van Neuten J, Xhonneux R, De Cree J, Verhaegen H et al. Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent, and selective beta 1-adrenergic antagonist. J Cardiovasc Pharmacol 1988; 11: 552–563.

    Article  CAS  Google Scholar 

  10. Bowman AJ, Chen CP, Ford GA . Nitric oxide mediated venodilator effects of nebivolol. Br J Clin Pharmacol 1994; 38: 199–204.

    Article  CAS  Google Scholar 

  11. Cockcroft JR, Chowienczyk PJ, Brett SE, Chen CP, Dupont AG, Van Nueten L et al. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism. J Pharmacol Exp Ther 1995; 274: 1067–1071.

    CAS  PubMed  Google Scholar 

  12. Tzemos N, Lim PO, MacDonald TM . Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. Circulation 2001; 104: 511–514.

    Article  CAS  Google Scholar 

  13. Ritter JM . Nebivolol: endothelium-mediated vasodilating effect. J Cardiovasc Pharmacol 2001; 38 (Suppl 3): S13–S16.

    Article  CAS  Google Scholar 

  14. Weiss RJ, Weber MA, Carr AA, Sullivan WA . A randomized, double-blind, placebo-controlled parallel-group study to assess the efficacy and safety of nebivolol, a novel beta-blocker, in patients with mild to moderate hypertension. J Clin Hypertens 2007; 9: 667–676.

    Article  CAS  Google Scholar 

  15. Saunders E, Smith WB, DeSalvo KB, Sullivan WA . The efficacy and tolerability of nebivolol in hypertensive African American patients. J Clin Hypertens 2007; 9: 866–875.

    Article  CAS  Google Scholar 

  16. Zanchetti A . Clinical pharmacodynamics of nebivolol: new evidence of nitric oxide-mediated vasodilating activity and peculiar haemodynamic properties in hypertensive patients. Blood Press Suppl 2004; 1: 17–32.

    Article  Google Scholar 

  17. Van Nueten L, Dupont AG, Vertommen C, Goyvaerts H, Robertson JI . A dose-response trial of nebivolol in essential hypertension. J Hum Hypertens 1997; 11: 139–144.

    Article  CAS  Google Scholar 

  18. Veverka A, Nuzum DS, Jolly JL . Nebivolol: a third-generation beta-adrenergic blocker. Ann Pharmacother 2006; 40: 1353–1360.

    Article  CAS  Google Scholar 

  19. McNeely W, Goa KL . Nebivolol in the management of essential hypertension: a review. Drugs 1999; 57: 633–651.

    Article  CAS  Google Scholar 

  20. Clement DL, De Buyzere ML, De Bacquer DA, de Leeuw PW, Duprez DA, Fagard RH et al. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med 2003; 348: 2407–2415.

    Article  Google Scholar 

  21. Asmar R, Boutelant S, Chaignon M, Guedon J, Topouchian J, Mallion JM et al. Repeated measurements of non-invasive ambulatory blood pressure: distinction between reproducibility and the proper effect of placebo. Blood Press Monit 1996; 1: 283–288.

    CAS  PubMed  Google Scholar 

  22. Grassi G, Trevano FQ, Facchini A, Toutouzas T, Chanu B, Mancia G . Efficacy and tolerability profile of nebivolol vs atenolol in mild-to-moderate essential hypertension: results of a double-blind randomized multicentre trial. Blood Press Suppl 2003; 2: 35–40.

    Article  Google Scholar 

  23. Lacourciere Y, Lefebvre J, Poirier L, Archambault F, Arnott W . Treatment of ambulatory hypertension with nebivolol or hydrochlorothiazide alone and in combination. A randomized, double-blind, placebo-controlled, factorial-design trial. Am J Hypertens 1994; 7: 137–145.

    Article  CAS  Google Scholar 

  24. Van Nueten L, Taylor FR, Robertson JI . Nebivolol vs atenolol and placebo in essential hypertension: a double-blind randomised trial. J Hum Hypertens 1998; 12: 135–140.

    Article  CAS  Google Scholar 

  25. Weiss RJ, Weber MA, Carr AA, Riggs B . Nebivolol in the treatment of patients with stage 1 and stage 2 hypertension. Results of a randomized double-blind, placebo-controlled study. Am J Hypertens 2005; 18: 96A.

    Article  Google Scholar 

  26. Greathouse M . Nebivolol efficacy and safety in patients with Stage I–II hypertension. Clin Cardiol, In press.

  27. Sica DA . Beta-blockers in hypertension: a reassessment of the benefit of combined alpha-/beta-blockade. J Clin Hypertens 2007; 9 (4 Suppl 4): 4–9.

    Article  CAS  Google Scholar 

  28. Preuss HG, Burris JF . Adverse metabolic effects of antihypertensive drugs. Implications for treatment. Drug Saf 1996; 14: 355–364.

    Article  CAS  Google Scholar 

  29. Pessina AC . Metabolic effects and safety profile of nebivolol. J Cardiovasc Pharmacol 2001; 38 (Suppl 3): S33–S35.

    Article  CAS  Google Scholar 

  30. Fogari R, Zoppi A, Lazzari P, Mugellini A, Lusardi P, Preti P et al. Comparative effects of nebivolol and atenolol on blood pressure and insulin sensitivity in hypertensive subjects with type II diabetes. J Hum Hypertens 1997; 11: 753–757.

    Article  CAS  Google Scholar 

  31. Lacourciere Y, Poirier L, Lefebvre J, Provencher P, Arnott W . Comparative effects of a new cardioselective beta-blocker nebivolol and nifedipine sustained-release on 24-h ambulatory blood pressure and plasma lipoproteins. J Clin Pharmacol 1992; 32: 660–666.

    Article  CAS  Google Scholar 

  32. Celik T, Iyisoy A, Kursaklioglu H, Kardesoglu E, Kilic S, Turhan H et al. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J Hypertens 2006; 24: 591–596.

    Article  CAS  Google Scholar 

  33. Black HR, Sica DA . A modern perspective on beta-blocker use in hypertension: clinical trials and their influence on clinical practice. J Clin Hypertens 2007; 9 (4 Suppl 4): 10–18.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

Bertek Pharmaceuticals Inc. (now part of Mylan Laboratories Inc.) provided all financial and material support for the research. Editorial assistance was provided by Strategic Medical Initiatives.

Author information

Authors and Affiliations

  1. Orange County Research Center, Tustin, CA, USA

    J M Neutel

  2. University of California, Irvine, CA, USA

    D H G Smith

  3. The Western Pennsylvania Hospital, Pittsburgh, PA, USA

    A H Gradman

Authors
  1. J M Neutel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D H G Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A H Gradman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J M Neutel.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Neutel, J., Smith, D. & Gradman, A. Adding nebivolol to ongoing antihypertensive therapy improves blood pressure and response rates in patients with uncontrolled stage I–II hypertension. J Hum Hypertens 24, 64–73 (2010). https://doi.org/10.1038/jhh.2009.33

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/jhh.2009.33

Keywords

This article is cited by

Search

Advanced search

Quick links